Here's my thought. When they're running the study, there's a good chance they'll use cogstate battery as established technique to compare against. IF the study is proven to be successful, it'll probably have impact on loyalties that Cogstate receives from healthcare segment? On the other hand, Eli Lily's published successful phase 2 clinical study result of their alzheimer's disease drug, donanemab. I know it'll be years from phase 3 but any successful alzheimer's drug will benefit cogstate.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.005(0.30%) |
Mkt cap ! $282.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.68 | $1.65 | $27.13K | 16.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 901 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 8514 | 6 |
View Market Depth
| Last trade - 11.29am 04/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |